articl
provid
overview
invit
lectur
intern
confer
antivir
research
sponsor
intern
societi
antivir
research
isar
held
raleigh
north
carolina
usa
may
begin
report
lectur
recipi
isar
three
major
award
held
memori
gertrud
elion
william
prusoff
follow
brief
summari
keynot
address
three
minisymposia
hepat
b
viru
research
triangl
park
challeng
hiv
infect
treatment
prevent
review
articl
simpli
provid
short
account
oral
present
gener
accompani
refer
scientif
literatur
descript
favor
treatment
outcom
taken
recommend
clinic
use
gertrud
elion
memori
award
lectur
collabor
antivir
studi
discoveri
drug
treat
cytomegaloviru
infect
john
c
drach
phd
univers
michigan
ann
arbor
michigan
usa
fig
gertrud
b
trudi
elion
born
new
york
citi
pleas
work
burrough
wellcom
co
base
new
york
concern
transfer
research
triangl
park
north
carolina
mani
mile
year
meet
site
howev
within
month
declar
home
north
carolina
award
nobel
prize
physiolog
medicin
pioneer
work
purin
biosynthesi
pave
way
discoveri
drug
treat
organ
reject
cancer
viral
diseas
focu
john
present
research
conduct
collabor
laboratori
ultim
led
invent
three
compound
discov
antivir
activ
human
cytomegaloviru
hcmv
later
enter
clinic
trial
bdcrb
pyranosid
phase
maribavir
phase
ii
iii
cyclopropavir
phase
major
collabor
includ
karen
biron
charl
shipman
leroy
townsend
jiri
zemlicka
date
five
fdaapprov
drug
treatment
hcmv
infect
cidofovir
fomivirsen
foscarnet
ganciclovir
valganciclovir
inspir
presenc
naturallyoccur
nucleotid
vitamin
research
benzimidazol
nucleosid
initi
medicin
chemist
led
synthesi
trichloro
analog
townsend
laboratori
univers
utah
later
discoveri
activ
hcmv
john
laboratori
much
work
laboratori
univers
michigan
establish
analog
bdcrb
excel
activ
hcmv
low
cytotox
surprisingli
found
inact
herp
virus
need
convers
triphosph
activ
hcmv
collabor
studi
karen
biron
burrough
wellcom
establish
unlik
mani
antivir
inhibit
viral
dna
synthesi
ganciclovir
gcv
compound
act
novel
mechan
inhibit
viral
dna
process
viral
resist
studi
reveal
viral
target
two
protein
form
complex
known
terminas
cut
newli
synthesis
hcmv
dna
unit
length
packag
virion
although
bdcrb
mani
desir
properti
vitro
poor
pharmacokinet
mice
monkey
due
hydrolysi
glycosid
bond
therefor
develop
human
use
much
addit
work
drach
townsend
laboratori
michigan
biron
group
burrough
wellcom
ultim
led
two
potenti
drug
candid
bdcrb
pyranosid
maribavir
fig
compound
excel
activ
hcmv
low
toxic
excel
pharmacokinet
clearli
mode
action
differ
markedli
gcv
quit
unexpectedli
differ
mechan
action
bdcrb
pyranosid
mechan
action
similar
parent
compound
bdcrb
inhibit
dna
process
contrast
maribavir
inhibit
dna
synthesi
albeit
indirectli
deriv
bdcrb
except
unnatur
lsugar
configur
mechan
action
involv
inhibit
viral
kinas
phosphoryl
anoth
viral
protein
phosphoryl
necessari
viral
dna
synthesi
thu
inhibit
maribavir
inhibit
viral
dna
synthesi
interestingli
also
kinas
activ
phosphoryl
gcv
resist
studi
confirm
singl
mutat
result
mutat
kinas
necessari
suffici
resist
maribavir
studi
resist
viru
alreadi
resist
bdcrb
passag
increas
concentr
maribavir
resist
viru
isol
strain
grew
rate
wildtyp
viru
resist
bdcrb
maribavir
expect
resist
bdcrb
due
known
mutat
howev
mutat
found
investig
show
singl
base
chang
necessari
suffici
resist
maribavir
role
encod
protein
unknown
amino
acid
mutat
middl
protein
similarli
biron
group
detect
resist
due
mutat
gene
research
studi
maribavir
summar
previou
icar
scientif
report
cyclopropavir
cpv
fig
synthes
laboratori
jiri
zemlicka
karmano
cancer
institut
detroit
michigan
guanosin
nucleosid
analog
activ
hcmv
unlik
benzimidazol
nucleosid
also
inhibit
epsteinbarr
viru
ebv
human
herpesviru
like
gcv
phosphoryl
kinas
encod
potent
vitro
vivo
ganciclovir
somewhat
differ
pattern
resist
one
resist
strain
key
mutat
form
stop
codon
result
truncat
kinas
protein
phosphoryl
cpv
effici
gcv
consider
lower
k
higher
v
max
interestingli
phosphoryl
cpv
monophosph
cpvmp
stereoselect
isom
cpvmp
form
singl
enzym
gmp
kinas
phosphoryl
cpmmp
diand
triphosph
contrast
acyclovir
gcv
requir
addit
cellular
enzym
convert
diphosph
activ
triphosph
cyclopropavir
current
phase
clinic
trial
treatment
hcmv
infect
memori
award
lectur
modifi
nucleosid
chemic
modifi
genom
piet
herdewijn
rega
institut
medic
research
ku
leuven
belgium
fig
icar
began
symposium
legaci
late
toni
establish
new
isar
award
medicin
chemistri
announc
awarde
senior
scientist
intern
statur
medicin
chemistri
made
innov
contribut
impact
antivir
drug
discoveri
develop
piet
therefor
first
receiv
award
late
potent
activ
bvdu
bvarau
herp
simplex
viru
type
varicella
zoster
viru
vzv
discov
work
motiv
piet
start
antivir
research
synthesi
carbocycl
bvdu
earli
synthes
sever
nucleosid
analog
bicycl
base
good
activ
vzv
emphasi
switch
investig
effect
modifi
sugar
ring
particular
synthesi
sixmemb
ring
contain
oxygen
doubl
bond
piet
show
exampl
compound
activ
vzv
hcmv
back
erik
de
clercq
show
piet
paper
aid
one
author
phil
furman
public
stimul
search
antihiv
compound
mani
compound
discov
potent
activ
good
select
indic
hiv
piet
work
first
structureact
relationship
antihiv
dideoxi
nucleosid
start
late
toni
synthesis
seri
phosphon
icar
erik
de
clercq
recal
work
led
ultim
tenofovir
becom
major
success
treat
hivinfect
patient
first
introduct
market
share
increas
well
singlepil
regimen
agre
way
forward
simplifi
therebi
enhanc
hiv
therapi
led
atripla
approv
complera
stribild
tenofovir
variou
prodrug
form
avail
countri
distribut
wide
known
hivinfect
popul
line
research
piet
synthes
phosphon
nucleosid
threos
sugar
moieti
show
antihiv
activ
rang
adenin
pmea
piet
work
taken
differ
pathway
possibl
link
sever
nucleotid
togeth
form
aptam
exampl
fig
antivir
nucleosid
ring
place
natur
furanos
could
incorpor
hexitol
nucleic
acid
hna
aptam
xray
studi
reveal
structur
hnarna
duplex
hnahna
duplex
latter
similar
overal
form
rnarna
duplex
base
sequenc
hnacontain
aptam
shown
potent
specif
inhibitor
transactiv
region
tar
mediat
transcript
normal
hiv
encod
protein
transactiv
transcript
tat
bind
cellular
factor
viral
tar
rna
regulatori
element
result
vastli
increas
rate
transcript
hiv
gene
hnacontain
aptam
prevent
interact
inhibit
hiv
replic
took
four
year
engin
polymeras
would
utilis
hna
assembl
strand
complementari
dna
templat
line
research
hexitolmodifi
sirna
shown
good
activ
vivo
antihbv
model
success
stimul
concept
may
possibl
gener
new
form
biolog
activ
dna
order
pursu
idea
cultur
system
twin
growth
chamber
devis
altern
nutrient
media
could
fed
chamber
cultur
one
chamber
could
use
seed
second
chamber
former
cultur
remov
exampl
aim
replac
thymin
fig
use
escherichia
coli
initi
nutrient
contain
thymin
cycl
seed
one
chamber
previou
one
proport
increas
day
gener
e
coli
thymin
replac
total
interest
outcom
altern
base
led
chang
genotyp
also
phenotyp
new
e
coli
cell
much
longer
origin
first
exampl
dna
polymeras
adapt
evolutionari
pressur
accept
nucleotid
analog
result
gener
new
live
organ
prusoff
young
investig
award
lectur
use
nucleotid
prodrug
enhanc
select
antihiv
hcv
agent
adrian
ray
gilead
scienc
inc
foster
citi
ca
usa
fig
adrian
start
lectur
photo
william
bill
prusoff
reminisc
day
bill
raymond
schinazi
yungchi
tommi
cheng
adrian
present
exampl
illustr
two
model
prodrug
strategi
transform
potenti
drug
much
improv
clinic
candid
first
prodrug
alter
distribut
pharmacolog
activ
nucleotid
analog
tissu
viral
infect
take
place
ontarget
away
tissu
result
advers
event
offtarget
second
prodrug
enabl
one
select
drug
candid
base
directli
intrins
properti
activ
nucleotidetriphosph
analog
via
bypass
ineffici
activ
phosphoryl
correspond
nucleosid
analog
sofosbuvir
sovaldi
prodrug
cmeump
approv
usa
decemb
treatment
patient
hepat
c
fine
exampl
prodrug
enhanc
activ
parent
compound
nucleosid
analogu
cmeu
poorli
activ
due
restrict
phosphoryl
monophosph
sofosbuvir
nucleotid
analogu
prodrug
cmeu
deliv
monophosph
cell
phosphoryl
effici
give
high
level
triphosph
inhibit
hcv
rna
polymeras
adrian
recal
much
impress
result
report
meet
american
associ
studi
liver
diseas
aasld
phase
ii
monotherapi
trial
patient
hcv
day
viral
load
reduc
log
log
mg
bid
mg
bid
respect
howev
day
polymeras
inhibitor
continu
reduc
viral
load
reach
reduct
log
hand
proteas
inhibitor
give
sustain
reduct
viral
load
start
increas
day
day
viral
load
log
less
baselin
nucleotid
analogu
two
advantag
class
inhibitor
high
genet
barrier
resist
select
due
hcv
rna
polymeras
highli
specif
natur
substrat
templat
specif
alter
extrem
evolutionari
pressur
see
section
also
nucleotid
analog
often
pangenotyp
activ
activ
site
hcv
polymeras
highli
conserv
exampl
prodrug
impact
discoveri
program
allow
target
deliveri
optim
intrins
properti
triphosph
adrian
present
histori
program
cadenin
analogu
compar
correspond
nnucleosid
replicon
assay
ec
valu
lm
lm
respect
howev
triphosph
equal
effect
hcv
polymeras
ic
valu
lm
replicon
system
triphosph
nnuc
form
effici
thu
explain
lower
activ
howev
primari
human
hepatocyt
phosphoryl
triphosph
effici
nnuc
illustr
import
use
primari
human
cell
seem
benign
vitro
toxic
profil
includ
inhibit
mitochondri
dna
polymerasegamma
signific
toxic
anim
collabor
gilead
craig
cameron
pennsylvania
state
univers
research
sought
identifi
toxic
target
ribonucleotid
analogu
includ
other
stop
phase
ii
trial
studi
show
correl
phase
ii
candid
latter
effici
incorpor
rna
mitochondri
rna
polymeras
correspond
natur
nucleotid
triphosph
also
effici
substrat
rate
atp
contrast
activ
nucleotid
analog
form
drug
approv
treatment
hcv
poor
substrat
ribavirin
poorli
incorpor
sofosbuvir
limit
detect
extens
vitro
cell
cultur
evalu
compound
could
save
expens
take
clinic
trial
understand
mitochondri
rna
polymeras
import
target
ribonucleotid
toxic
gilead
team
sought
analog
incorpor
polymeras
ad
cn
group
posit
chang
activ
hcv
polymeras
inhibitor
ic
lm
reduc
incorpor
mitochondri
rna
assay
howev
absenc
nucleotid
prodrug
bypass
first
phosphoryl
step
result
disubstitut
nucleosid
analog
would
drug
candid
effici
activ
cell
applic
nucleotid
prodrug
strategi
allow
nucleotid
pursu
oral
absorpt
deliveri
monophosph
hepatocyt
high
hepat
extract
criteria
use
part
prodrug
optim
process
nucleotid
prodrug
mixtur
diastereoisom
phosphor
well
absorb
dog
compar
prehepat
posthepat
plasma
drug
level
absorb
drug
taken
liver
insid
cell
convert
correspond
monophosph
effici
convert
triphosph
h
triphosph
level
remain
ic
valu
pure
stereoisom
select
later
name
phase
ii
trial
mg
bid
day
mean
reduct
hcv
load
log
two
subject
achiev
hcv
rna
iu
ml
howev
pharmacokinet
antivir
respons
highli
variabl
wherea
activ
result
disappoint
clinic
proof
concept
observ
term
safeti
markedli
improv
safeti
profil
rel
progress
chronic
toxicolog
studi
rat
dog
rel
high
dose
stori
illustr
nucleotid
prodrug
enabl
progress
candid
also
complex
predict
behavior
nucleotid
prodrug
across
speci
one
wonder
cell
cultur
test
anim
model
may
predict
variabl
select
famciclovir
prodrug
penciclovir
one
potenti
prodrug
reject
pharmacokinet
rat
vari
wide
individu
anim
vere
hodg
et
al
recent
public
adrian
team
highlight
metabol
carboxylesteras
enzym
highli
express
human
small
intestin
uniformli
express
differ
anim
speci
possibl
reason
highli
variabl
suboptim
intestin
absorpt
human
murakami
et
al
focu
adrian
talk
switch
hiv
last
year
north
america
hivinfect
popul
chang
becom
older
year
old
vs
like
obes
everi
usa
state
adult
led
shift
focu
antiretrovir
therapi
art
sole
control
hiv
replic
includ
toler
older
possibl
obes
patient
first
exampl
given
hiv
applic
differ
prodrug
strategi
markedli
chang
distribut
even
deliv
pharmacolog
activ
nucleotid
analog
first
approv
prodrug
tenofovir
tfv
tfv
disoproxil
fumar
tdf
recent
tfv
alafenamid
taf
progress
clinic
develop
key
differ
properti
two
prodrug
stabil
plasma
halfliv
min
respect
even
short
halflif
tdf
gave
better
deliveri
tfv
cell
indic
hiv
ec
valu
cell
cultur
assay
clearli
room
improv
ec
valu
tfv
tdf
taf
lm
respect
wherea
gain
cell
cultur
ec
valu
may
modest
gain
increas
stabil
taf
allow
load
ontarget
cell
tissu
eg
lymph
node
longer
period
time
result
increas
lymphoid
cell
tissu
level
greatli
reduc
circul
tfv
level
lead
less
exposur
offtarget
tissu
eg
kidney
monotherapi
studi
oral
dose
tdf
mg
taf
mg
plasma
tfv
auc
reduc
nghml
respect
wherea
reduct
hiv
load
baselin
improv
log
log
copiesml
respect
reflect
effici
deliveri
taf
target
cell
tissu
clearli
lower
dose
taf
mg
rel
tdf
mg
give
taf
mark
advantag
consid
combin
pill
therapi
understand
mark
differ
prodrug
make
taf
exampl
adrian
went
describ
prodrug
approach
transform
new
nucleotid
project
intrins
properti
pharmacologicallyact
nucleotid
analog
optim
start
point
good
activ
wildtyp
resist
hiv
strain
activ
inhibitor
mitochondri
polymerasegamma
compar
known
structur
hiv
rt
mitochondri
polymerasegamma
differ
bind
pocket
note
led
f
ad
fig
compar
tfv
less
activ
wildtyp
hiv
maintain
better
activ
resist
strain
multipl
thymidin
analog
resist
mutat
importantli
inact
ic
lm
mitochondri
polymeras
gamma
prodrug
synthes
evalu
metabol
studi
dog
intraven
oral
administr
enantiom
test
separ
dog
led
select
wherea
tfv
effici
utilis
renal
uptak
transport
poorli
taken
kidney
advers
renal
find
observ
prodrug
studi
rat
dog
monkey
highest
dose
test
mg
mg
mgkg
daili
respect
summari
work
given
exampl
prodrug
approach
use
success
increas
select
load
ontarget
tissu
vs
offtarget
tissu
increas
activ
via
bypass
metabol
constraint
adrian
present
case
prodrug
strategi
abl
fulfil
full
potenti
select
activ
triphosph
analog
enabl
progress
clinic
candid
keynot
speaker
david
margoli
myron
cohen
fig
david
margoli
univers
north
carolina
nc
usa
hivinfect
patient
longlast
reservoir
hiv
form
integr
viral
dna
rest
memori
cell
host
immun
system
therefor
even
possibl
elimin
viral
replic
reservoir
hiv
would
remain
may
reservoir
longliv
cell
date
one
known
hiv
patient
cure
infect
berlin
patient
treat
cancer
chemotherapi
follow
bonemarrow
transplant
chemotherapi
greater
chanc
remov
cell
bone
marrow
donor
although
patient
continu
sign
hiv
infect
hardli
viabl
treatment
option
hivinfect
patient
even
subject
hiv
replic
well
control
therapi
detect
plasma
viremia
appear
decay
time
least
two
year
improv
sensit
assay
hiv
billion
lymphocyt
mix
antibodi
attach
magnet
bead
select
cell
billion
cell
limit
detect
copi
hiv
rnamillion
cell
limit
quantit
copiesmillion
cell
reduc
reservoir
hiv
suggest
activ
integr
hiv
rest
cell
would
give
renew
hiv
rna
synthesi
possibl
result
cell
death
either
due
viral
cytopath
effect
result
hivspecif
immun
respons
small
clinic
trial
set
test
hypothesi
vorinostat
vor
clinic
approv
drug
treat
certain
cancer
shown
bind
activ
site
histon
deacetylas
singl
dose
increas
hiv
rna
mean
subject
elect
continu
multipl
dose
vor
dose
acetyl
histon
activ
hiv
rna
synthesi
becam
refractori
therapi
also
known
proport
cell
latent
hiv
activ
wherea
singl
vor
dose
increas
express
hiv
rna
effect
therapi
remov
hiv
reservoir
myron
cohen
univers
north
carolina
nc
usa
myron
note
million
new
hiv
infect
year
context
anal
sex
may
import
factor
one
virion
hiv
infect
within
week
rapid
viru
replic
throughout
bodi
latent
hiv
reservoir
founder
viru
alreadi
form
although
anal
sex
associ
homosexu
coupl
myron
point
uncommon
amongst
heterosexu
coupl
although
behavior
educ
encourag
never
whole
answer
variou
approach
prevent
hiv
transmiss
evalu
monoclon
antibodi
broad
neutralis
antibodi
bnab
vaccin
may
potenti
prevent
transmiss
progress
made
dapivirin
ring
contain
tdf
design
stay
vagina
month
phase
iii
trial
ongo
longact
hiv
integras
inhibitor
gsk
gener
known
gsk
administ
im
everi
month
twoyear
safeti
trial
requir
phase
trial
complet
phase
ii
trial
plan
analog
tuberculosi
therapi
infecti
state
disabl
prior
complet
cure
one
wonder
hiv
transmiss
rate
may
decreas
effect
art
use
hiv
prevent
trial
network
hptn
initi
studi
hptn
enrol
hiv
serodiscord
coupl
coupl
one
member
hivinfect
hivuninfect
mostli
heterosexu
coupl
infect
partner
well
enough
requir
immedi
art
coupl
randomis
either
immedi
delay
art
group
receiv
care
includ
counsel
safe
sex
practic
free
condom
treatment
sexual
transmit
infect
regular
hiv
test
may
announc
hiv
transmiss
delay
art
group
coupl
compar
immedi
art
group
coupl
reduct
case
hiv
strain
link
partner
first
randomis
clinic
trial
show
treat
hivinfect
individu
art
reduc
risk
hiv
transmiss
uninfect
partner
even
safersex
counsel
pregnanc
delay
art
group
despit
group
incent
safersex
follow
announc
result
infect
particip
offer
art
myron
report
annual
review
studi
delay
art
group
total
case
hiv
transmiss
hiv
strain
link
partner
case
unlink
transmiss
one
case
hiv
transmiss
immedi
art
group
infect
detect
day
studi
investig
suggest
infect
event
day
clearli
earli
art
highli
benefici
cdc
guidelin
recommend
hiv
infect
patient
art
minisymposium
hepat
b
viru
anna
lok
univers
michigan
mi
usa
number
peopl
infect
hbv
worldwid
estim
cdc
million
declin
due
vaccin
usa
vaccin
use
led
steadi
declin
rate
new
infect
decreas
resid
today
contrast
preval
chronic
hepat
b
among
immigr
remain
high
decreas
trend
infect
acquir
earli
life
chronic
infect
norm
high
viral
load
associ
progress
liver
cancer
fdaapprov
drug
treat
chronic
hbv
infect
includ
entecavir
etv
emtricitabin
ftc
tdf
sever
year
continu
therapi
hbeag
loss
achiev
patient
hbsag
loss
ultim
goal
seen
cure
still
distant
prospect
patient
howev
cirrhosi
reduc
longterm
antivir
treatment
one
tdf
trial
year
patient
liver
biopsi
show
patient
improv
fibrosi
score
unit
patient
worsen
tdf
use
year
without
detect
hbv
resist
make
one
first
line
drug
tdf
gener
well
toler
rare
side
effect
includ
nephrotox
see
possibl
switch
taf
approv
reduct
bone
miner
densiti
rare
lactic
acidosi
despit
major
progress
made
hbv
therapi
remain
variou
challeng
one
cost
tdf
therapi
pharmaci
claim
show
adher
problem
dose
use
less
dose
prescrib
lack
accur
predict
hbv
diseas
progress
individu
hbv
dna
integr
human
genom
earli
stage
infect
fortun
integr
viral
dna
usual
complet
viral
genom
patient
achiev
hbsag
loss
rare
relaps
stefan
mehrl
univers
heidelberg
germani
stephan
urban
head
hepat
b
research
group
univers
heidelberg
origin
schedul
give
present
chronic
hbvinfect
subject
coinfect
hepat
delta
viru
hdv
defect
viru
replic
presenc
hbv
current
antivir
drug
inhibit
hdv
recent
heparan
sulphat
proteoglycan
hspg
shown
essenti
bind
hbv
hdv
primari
hepatocyt
human
sodium
taurochol
cotransport
polypeptid
hntcp
identifi
function
receptor
hbv
hdv
hntcp
also
design
solut
carrier
protein
hntcp
shown
bind
factor
domain
hbv
l
envelop
protein
interact
found
essenti
hbv
hdv
infect
wherea
hbv
replic
poor
cell
line
deriv
hepatocyt
eg
hntcp
usual
weakli
express
hbv
replic
possibl
primari
human
hepatocyt
critic
discoveri
overexpress
hntcp
cell
confer
suscept
hbv
hdv
infect
myrcludexb
lipopeptid
deriv
amino
acid
residu
region
hbv
l
protein
quickli
within
min
target
liver
develop
liver
imag
drug
target
also
act
entri
inhibitor
hbv
hdv
interrupt
bind
hbv
l
protein
hntcp
specif
inhibit
hntcpmediat
taurochol
transport
effect
hbv
replic
much
greater
myrcludexb
activ
investig
vivo
use
scid
mice
reconstitut
human
hepatocyt
prophylact
treatment
one
infect
hepatocyt
seen
follow
therapeut
treatment
week
postinfect
isol
infect
cell
end
therapi
infect
seem
spread
neighbor
cell
myrcludexb
synthesis
g
scale
toxicolog
evalu
chimpanze
complet
clinic
trial
initi
phase
trial
use
mg
dose
myrcludexb
well
toler
result
phase
trial
due
report
later
year
doserang
phase
ii
trial
start
kyongmi
chang
univers
pennsylvania
pa
usa
antihb
antibodi
clearli
play
critic
role
control
hbv
diseas
presenc
accept
indic
effect
cure
howev
antibodi
appear
late
diseas
cours
must
limit
role
earli
stage
diseas
role
tcell
respons
contrast
virus
delay
onset
week
rather
day
cell
regul
adapt
respons
cell
attack
hbvinfect
cell
nation
institut
diabet
digest
kidney
diseas
niddk
part
usa
nation
institut
health
nih
support
prospect
clinic
trial
investig
hbvspecif
cell
respons
cours
hbv
diseas
clear
cell
differ
rel
hbv
genotyp
cell
respons
highest
acut
hbv
infect
chronic
phase
hbv
diseas
cell
respons
remain
suppress
conclus
lot
player
immun
control
hbv
infect
rel
contribut
adapt
control
hbv
replic
still
larg
unknown
diversifi
hepat
b
pipelin
current
effort
explor
novel
mechan
andrea
andi
cuconati
institut
hepat
viru
research
pennsylvania
commonwealth
institut
pa
usa
current
hbv
therapi
use
nucleotid
antivir
highli
effect
control
infect
cure
defin
hbsag
seroconvers
remain
elus
best
year
rate
approach
need
myrcludexb
see
section
lead
entri
inhibitor
encapsid
inhibitor
enter
clinic
trial
addit
studi
novel
nucleotid
analogu
ongo
hbv
field
transform
recent
introduct
cellbas
antivir
assay
stefan
mehrl
see
section
lead
way
assay
readout
need
optim
highthroughput
screen
ht
alreadi
assay
shown
hit
compound
inhibit
encapsid
viral
rna
hbv
virion
contain
partli
doubl
strand
ds
dna
reversetranscript
rna
dna
occur
within
capsid
within
cell
hbv
dna
transport
nucleu
viral
dna
form
coval
close
circl
cccdna
two
specif
inhibitor
cccdna
format
found
current
nucleotid
antihbv
compound
give
larg
reduct
hbv
dna
plasma
minim
reduct
level
hb
antigen
log
contrast
one
hit
inhibit
surfac
antigen
product
genom
replic
structureactivityrelationship
sar
studi
given
current
lead
compound
conclus
cellbas
assay
complet
replic
hbv
markedli
improv
screen
antihbv
compound
although
optim
still
need
give
ht
capabl
adam
zlotnick
univers
indiana
usa
last
year
much
progress
toward
understand
critic
role
hbv
core
protein
much
protect
coat
genom
play
major
role
hbv
life
cycl
core
protein
amino
acid
long
known
cp
first
amino
acid
involv
core
assembl
wherea
last
residu
rich
serin
arginin
bind
rna
phosphoryl
serin
particularli
requir
specif
packag
full
length
hbv
rna
complex
polymeras
revers
transcriptas
pregenom
rna
rtpgrna
rtpgrna
complex
initi
encapsid
core
consist
mainli
cp
also
includ
protein
adam
show
us
comput
model
core
use
differ
colour
highlight
variou
critic
compon
insid
core
area
highest
densiti
highlight
red
repres
polymeras
attach
inner
surfac
core
protein
core
shown
blue
current
think
polymeras
initi
act
revers
transcriptas
attach
guid
insid
railway
track
enabl
polymeras
jump
end
rna
start
revers
transcript
dna
jump
end
start
never
complet
replic
complementari
dna
strand
selfassembl
core
energet
downhil
process
somewhat
surprisingli
possibl
get
mutat
core
even
stabl
rt
activ
reduc
phenylpropenamid
deriv
fill
pocket
core
stabil
similar
chang
amino
acid
mutant
presenc
core
assembl
occur
faster
henc
known
core
assembl
enhanc
adam
mention
term
much
love
industri
prefer
core
assembl
inhibitor
regardless
whole
capsid
structur
chang
bind
drug
molecul
requir
make
core
nonfunct
seem
easier
find
compound
enhanc
core
assembl
inhibitor
target
cccdna
cure
chronic
hepat
b
massimo
levrero
sapeinza
universita
di
roma
itali
current
hbv
therapi
choic
tdf
alon
etv
drug
extens
safeti
record
use
year
howev
nucleosidenucleotid
analog
limit
log
reduct
level
hbv
cccdna
halflif
hbv
cccdna
seem
long
still
unknown
hbv
replic
parallel
host
gene
express
involv
acetyl
histon
exampl
h
h
host
transcript
factor
viral
protein
bind
cccdna
massimo
summar
variou
assay
studi
differ
stage
cccdna
replic
cycl
potenti
assay
would
allow
studi
variou
approach
reduc
clear
cccdna
silenc
cccdna
prevent
format
new
cccdna
would
eventu
remov
dilut
cell
death
proofofconcept
known
epigenet
compound
act
transcript
inhibitor
shown
cccdna
silenc
reduc
histon
acetyl
cccdna
becom
compact
allow
transcript
approach
mimic
partli
therapi
interferon
research
still
earli
stage
due
time
constraint
next
two
speaker
ask
present
brief
summari
john
morrey
utah
state
univers
ut
usa
describ
four
mous
model
stage
life
cycl
hbv
studi
chimer
mous
model
human
hepatocyt
use
howev
model
lack
potenti
studi
immun
system
expens
stephan
menn
georgetown
univers
dc
usa
describ
woodchuck
model
woodchuck
hepat
viru
whv
resembl
human
viru
diseas
anim
mani
similar
human
neonat
infect
becom
chronic
case
chronic
case
virtual
lifetim
risk
develop
cancer
time
scale
year
chronic
infect
follow
cancer
year
use
microbicid
activ
area
research
prevent
transmiss
hiv
david
katz
duke
univers
nc
usa
describ
mathemat
model
may
aid
drug
product
design
exampl
assum
microbicid
gel
micron
thick
epithelium
micron
stroma
connect
tissu
micron
partit
coeffici
gel
epithelium
known
possibl
model
drug
transfer
suggest
variou
paramet
exampl
size
subject
may
modifi
drug
deliveri
import
differ
disciplin
work
togeth
exampl
biophysicist
behavior
scientist
biophys
help
understand
complex
physic
phenomena
human
behavior
complex
highli
variabl
ralph
baric
univers
north
carolina
nc
usa
note
particular
infect
agent
exampl
noroviru
nov
may
caus
subclin
seriou
diseas
differ
individu
gener
anim
model
design
give
consist
outcom
rather
aim
mimic
genet
divers
found
human
subject
collabor
effort
mice
founder
strain
includ
wildderiv
strain
select
founder
laboratori
strain
deriv
ultim
singl
femal
mous
ca
suscept
founder
strain
sever
acut
respiratori
syndrom
coronaviru
sarscov
differ
wide
ld
founder
strain
crossbr
although
ca
gene
equal
distribut
among
new
mous
line
gene
combin
seen
previous
infect
mice
differ
founder
strain
constant
sarscov
inoculum
measur
viru
load
set
time
infect
correl
viru
load
diseas
measur
vascular
cuf
possibl
relat
effect
chromosom
hope
identif
import
gene
may
achiev
keep
viru
inoculum
constant
system
better
repres
clinic
spectrum
diseas
use
system
evalu
potenti
vaccin
found
mice
age
one
year
could
protect
howev
rang
effect
good
protect
inact
variat
may
give
represent
human
divers
angela
kashuba
univers
north
carolina
chapel
hill
nc
usa
four
clinic
studi
truvada
combin
pill
contain
tdf
emtricitabin
ftc
taken
daili
prevent
hiv
transmiss
known
preexposur
prophylaxi
prep
adher
rate
unexpectedli
poor
four
studi
particularli
low
studi
includ
risk
women
exampl
one
studi
high
adher
defin
subject
take
least
drug
dose
achiev
subject
possibl
reason
may
appar
risk
sideeffect
long
consent
form
includ
page
sideeffect
percept
subject
individu
particularli
risk
infect
hiv
importantli
trial
confirm
concept
prep
could
effect
protect
subject
gener
take
dosesweek
protect
albeit
much
less
subject
take
dosesweek
adher
rate
report
subject
appreci
higher
rate
evidenc
drug
blood
level
measur
taken
next
dose
ie
h
previou
dose
attempt
better
understand
model
data
drug
concentr
tdftfv
ftc
variou
tissu
measur
ratio
drug
concentr
blood
tissu
sampl
differ
greatli
tdftfv
less
variat
ftc
concentr
ratio
tdftfv
rectal
tissu
vagin
tissu
ftc
ratio
respect
consid
possibl
consequ
miss
dose
time
scale
hiv
infect
import
factor
thought
hiv
take
h
reach
epitheli
cell
clearli
adher
critic
factor
efficaci
realtim
object
method
measur
adher
urgent
need
clinic
studi
initi
novel
nucleosid
analog
exhibit
broadspectrum
antivir
activ
confer
postexposur
protect
ebola
marburg
virus
travi
k
warren
usamriid
fort
detrick
md
usa
ebola
marburg
virus
member
filoviru
famili
even
recent
outbreak
diseas
includ
current
ebola
epidem
west
africa
care
worker
becom
infect
die
drug
investig
treat
diseas
progress
fda
anim
rule
cnucleosid
adenin
analog
fig
progress
biocryst
pharmaceut
inc
warren
et
al
cell
cultur
assay
activ
ebola
marburg
virus
ec
ca
lm
lm
detect
incorpor
host
dna
rna
rat
effici
activ
phosphoryl
triphosph
primerextens
assay
readthrough
beyond
singl
residu
effect
chain
termin
first
residu
templat
two
consecut
uridin
residu
test
rodent
nonhuman
primat
model
marburg
hemorrhag
fever
mice
dose
respons
mgdose
bid
full
protect
two
higher
dose
survivor
respect
experi
dose
start
differ
time
h
preinfect
h
postinfect
vs
placebo
placebotr
mice
die
day
one
survivor
treat
group
percent
surviv
respect
guinea
pig
bid
treatment
start
differ
time
h
preinfect
h
postinfect
full
protect
surviv
preinfect
h
group
reduc
efficaci
later
start
time
cynomolgu
monkey
treatment
start
h
postinfect
placebo
group
anim
die
within
day
treat
group
viru
load
reduc
log
one
late
death
h
group
monkey
surviv
variou
marker
potenti
organ
damag
reduc
treat
group
encourag
result
toxicolog
trial
recent
complet
without
seriou
concern
biocryst
develop
fda
anim
rule
inden
work
ongo
ask
viral
resist
travi
explain
ethic
permiss
creat
resist
strain
marburg
viru
sampl
collect
monkey
sequenc
look
mutat
indic
drug
resist
yet
mitochondri
toxic
examin
similar
bone
marrow
transplant
initi
seem
cure
hiv
detect
day
respect
latent
hiv
surviv
variou
longliv
cell
decad
especi
memori
cell
cell
prolifer
integr
hiv
genom
duplic
cell
divid
cell
surviv
long
hiv
remain
silent
compound
known
activ
tcell
toxic
becom
clinic
therapi
howev
latencyrevers
agent
lra
greater
specif
ideal
activ
integr
hiv
lead
death
hivcontain
tcell
remain
anoth
possibl
perhap
less
popular
view
continu
low
rate
hiv
replic
two
clinic
studi
initi
subject
undetect
plasma
hiv
level
raltegravir
hiv
integras
inhibitor
ad
background
therapi
latent
hiv
mostli
integr
host
dna
hiv
may
also
form
episom
circular
dna
proport
circular
form
increas
raltegravir
treatment
two
clinic
studi
subject
respect
detect
hiv
circl
decay
impli
de
novo
infect
cell
ongo
hand
art
work
well
evid
sequenc
evolut
hiv
circl
week
possibl
raltegravir
induc
singl
round
hiv
replic
give
increas
hiv
circl
derek
sloan
gilead
scienc
foster
citi
ca
usa
like
vorinostat
vor
romidepsin
rmd
histon
deacetylas
inhibitor
use
clinic
treat
cancer
memori
cell
taken
hiv
subject
suppress
art
exvivo
treatment
rmd
nm
induc
increas
intracellular
hiv
rna
persist
h
contrast
much
higher
concentr
vor
lm
gave
lower
respons
transient
rmd
also
increas
level
extracellular
hiv
rna
virion
encouragingli
exvivo
induct
latent
viru
seen
rmd
concentr
level
drug
achiev
human
clinic
dose
rmd
accordingli
phase
iii
trial
hivinfect
subject
art
rmd
gave
better
sustain
respons
vor
cell
contain
hiv
proviru
activ
although
far
low
percentag
elimin
latent
hiv
reservoir
hope
combin
lra
give
improv
result
exvivo
cell
assay
may
give
better
clinic
efficaci
gilead
scientist
start
screen
novel
lra
identifi
hit
ht
research
lead
earli
stage
gilead
worker
also
investig
approach
exampl
tolllik
receptor
agonist
act
immun
stimul
although
evalu
phase
ii
studi
treatment
chronic
hbv
infect
potenti
effect
hiv
reservoir
investig
sivinfect
monkey
oral
dose
agonist
induc
activ
immun
effector
cell
cell
nk
cell
base
data
agonist
investig
effect
latent
siv
reservoir
monkey
good
virolog
suppress
anoth
approach
use
antienvelop
antibodi
broadli
neutralis
antibodi
bnab
effect
prevent
siv
infect
viral
load
low
less
effect
highload
viru
challeng
addit
prophylact
cmvvectorbas
siv
vaccin
effect
prevent
siv
infect
rhesu
monkey
similar
vaccin
test
vivo
effect
latent
siv
reservoir
summari
lra
abl
activ
hiv
proviru
memori
cell
therebi
may
enhanc
recruit
immun
effector
cell
destroy
proviruscontain
cell
howev
cure
hiv
infect
still
distant
prospect
furthermor
latent
hiv
reservoir
heterogen
combin
approach
like
requir
gerardo
garcialerma
center
diseas
control
prevent
atlanta
ga
usa
proofofconcept
studi
prep
mostli
conduct
nonhuman
primat
use
either
model
singl
highdos
infect
challeng
repeat
low
inocul
tissu
cultur
infect
dose
tcid
sinc
rhesu
macaqu
model
use
long
seri
investig
studi
monkey
treat
daili
either
oral
tdf
tdfftc
given
weekli
siv
inoculum
rectal
tdfftc
gave
longer
delay
infect
tdf
alon
use
vagin
infect
rout
tdf
ftc
gave
protect
contrast
far
less
protect
clinic
trial
one
possibl
reason
may
women
contracept
inject
depot
medroxyprogesteron
acet
dmpa
studi
macaqu
monkey
given
dmpa
confirm
dose
tdvftc
gave
good
drug
level
plasma
vagin
secret
therefor
explain
poor
protect
clinic
trial
macaqu
model
use
success
investig
variou
situat
present
clinic
macaqu
coinfect
siv
bacteria
treat
tdfftc
week
good
complet
protect
ftcresist
viru
tdfftc
remain
protect
case
ftcresist
viru
increas
suscept
tdf
mutant
hiv
protect
low
inoculum
partial
protect
ca
high
inoculum
wherea
daili
dose
seem
accept
patient
live
hiv
anoth
option
prep
desir
gener
known
hiv
integras
inhibitor
formul
nanoparticl
provid
inject
drug
depot
macaqu
model
inject
monthli
gave
full
protect
repeat
rectal
vagin
exposur
metabol
much
slower
human
macaqu
expect
remain
effect
human
three
month
phase
studi
confirm
drug
level
remain
predict
effect
level
dose
interv
phase
ii
trial
plan
anoth
approach
use
vagin
ring
clinic
use
contracept
devic
year
macaqu
model
tdfcontain
ring
replac
everi
week
gave
full
protect
phase
iii
trial
initi
anoth
option
elvitegravir
evg
taf
evalu
biodegrad
polym
although
daili
dose
tdfftc
prove
suffici
success
prep
clinic
use
prove
prep
achiev
aim
encourag
progress
option
courtney
fletcher
univers
nebraska
omaha
ne
usa
atripla
first
tripl
combin
pill
taken
daili
hiv
therapi
contain
tdf
ftc
efavirenz
efv
macaqu
model
use
investig
differ
tissu
distribut
drug
viral
replic
may
continu
wherev
drug
concentr
lowest
two
approach
tissu
homogen
tissu
cell
tissu
homogen
give
intracellular
extracellular
drug
amount
tissu
mononuclear
cell
mnc
collect
intracellular
drug
concentr
measur
approach
prefer
courtney
option
may
constrain
sampl
size
drug
concentr
may
underestim
exampl
raltegravir
mnc
wash
time
drug
concentr
low
much
higher
raltegravir
concentr
found
mnc
clean
rapid
spin
oil
compar
oil
spin
repeat
wash
oil
process
give
higher
drug
level
typic
higher
follow
initi
studi
macaqu
clinic
studi
subject
investig
distribut
drug
atripla
peripher
blood
mononuclear
cell
pbmc
variou
tissu
see
subject
data
time
reduc
hiv
load
copiesml
plasma
time
month
lymphoid
tissu
much
slower
rate
hiv
declin
also
patient
variabl
note
faster
respond
higher
drug
level
drug
may
absorb
gastrointestin
tract
either
go
via
portal
vein
liver
blood
circul
via
lymphoid
system
blood
flow
time
faster
lymphoid
flow
partitioncoeffici
logp
drug
absorpt
tend
via
blood
rout
prodrug
approach
use
alter
absorpt
tfv
stabil
prodrug
tdf
taf
influenc
rel
concentr
lymphoid
tissu
see
year
three
major
award
lectur
exemplifi
strength
icar
cover
differ
area
research
john
drach
elion
award
describ
journey
earli
day
antivir
research
led
identif
novel
mode
antivir
action
envisag
previous
piet
herdewijn
award
use
evolutionari
pressur
select
dna
polymeras
accept
novel
nucleosid
analog
replac
thymin
led
gener
new
form
e
coli
suggest
work
import
implic
convent
antivir
research
hiv
hcv
proteas
inhibitor
genet
barrier
limit
abil
viral
proteas
substrat
viral
polyprotein
cleavag
site
comut
viru
becom
resist
antivir
drug
far
polymeras
inhibitor
suffer
fate
work
show
poor
choic
nucleotid
analog
could
result
resist
viru
new
type
rna
drug
replac
natur
nucleosid
adrian
ray
prusoff
award
describ
work
gilead
demonstr
prodrug
concept
markedli
improv
efficaci
safeti
potenti
drug
progress
hiv
hcv
therapi
remark
keynot
address
tackl
two
emerg
area
hiv
research
david
margoli
summar
work
aim
erad
hiv
infect
subject
myron
cohen
describ
current
progress
approach
prevent
hiv
transmiss
found
present
inform
stimul
hiv
cure
still
seem
distant
prospect
contrast
prior
exposur
prophylaxi
prep
shown
achiev
aim
although
need
daili
dose
barrier
success
gerardo
garcialerma
describ
recent
progress
like
radic
chang
prospect
therapeut
conveni
success
tdfcontain
vagin
ring
need
replac
month
evalu
anoth
excit
prospect
formul
longlast
inject
phase
trial
confirm
drug
may
administ
interv
absenc
proven
hiv
vaccin
prep
drug
becom
promis
strategi
reduc
hiv
infect
rate
among
highrisk
popul
confer
also
includ
three
interest
minisymposia
hepat
b
viru
research
triangl
park
challeng
hiv
infect
treatment
prevent
innov
year
session
devot
european
train
network
euvirna
introduc
frank
van
kuppeveld
euvirna
fellow
attend
icar
gave
short
present
session
inform
pleas
see
isar
news
septemb
issu
antivir
research
account
frank
van
kuppeveld
mani
year
clinic
symposium
major
highlight
icar
report
icar
express
hope
regard
hcv
therapi
prospect
first
nucleotid
analogu
licens
time
next
icar
meet
combin
nucleotid
analogu
inhibitor
look
set
transform
hcv
therapi
across
genotyp
hiv
singlepil
oncedaili
regimen
follow
quickli
decemb
sofosbuvir
sovaldi
first
nucleotid
analog
approv
usa
food
drug
administr
fda
treatment
patient
hcv
approv
european
union
follow
soon
afterward
januari
inhibitor
ledipasvir
formul
singl
fixeddos
combin
pill
sofosbuvir
progress
quickli
clinic
trial
remark
progress
achiev
sinc
icar
disappoint
discov
present
topic
year
icar
paper
sofia
part
symposium
antivir
research
hepat
c
next
step
toward
global
erad
emphas
recent
success
complet
therapi
sustain
virolog
respons
week
regard
cure
hcvinfect
patient
combin
sofosbuvirledipasvir
shown
remark
result
clinic
trial
rang
across
genotyp
combin
well
toler
nda
sofosbuvirledipasvir
combin
pill
submit
recent
recal
previou
antivir
trial
intentiontotreat
analys
show
success
rate
perhap
similar
hcv
symposium
antivir
research
hope
icar
held
rome
minisymposium
includ
account
remark
progress
would
interest
updat
clinic
impact
combin
therapi
hcv
assess
prospect
global
erad
hcv
besid
one
disappoint
mani
excel
present
would
like
add
thank
isar
offic
confer
committe
organ
anoth
interest
success
icar
